← Back to guidelines
Hematology37 papers

Hereditary thrombocytopenic disorder

Last edited: 4/15/2026

Overview

Hereditary thrombocytopenic disorders encompass a range of genetic conditions characterized by impaired platelet production or function, leading to thrombocytopenia and increased bleeding risk 1.

Diagnosis

  • Genetic testing for specific mutations (e.g., WAS, ITGA2B, THPO) 1.
  • Complete blood count (CBC) showing low platelet count 1.
  • Bone marrow examination to assess megakaryocyte morphology and function 1.
  • Peripheral blood smear to evaluate platelet morphology 1.
  • Management

  • First-line treatments: Corticosteroids for immune-mediated thrombocytopenia 1.
  • Second-line treatments: Immune globulin intravenous (IVIG) for short-term control 1.
  • Platelet transfusions: For acute bleeding episodes 1.
  • Splenectomy: Considered in severe cases unresponsive to medical therapy 1.
  • Special Populations

  • Pregnancy: Close monitoring required; management strategies may include IVIG and corticosteroids 1.
  • Pediatrics: Early diagnosis crucial; tailored treatment plans considering growth and development 1.
  • Elderly: Increased risk of bleeding; cautious approach to invasive procedures and medication side effects 1.
  • Comorbidities: Tailor treatment to manage coexisting conditions while addressing thrombocytopenia 1.
  • Key Recommendations

  • Utilize genetic testing for definitive diagnosis and family screening 1 (Evidence: Strong).
  • Initiate corticosteroid therapy as first-line management for immune-mediated forms 1 (Evidence: Strong).
  • Consider splenectomy in patients with severe, refractory thrombocytopenia after exhausting medical options 1 (Evidence: Moderate).
  • References

    1 Poncz M, Iannone R, Werner EM. Hematology grants workshop. Hematology. American Society of Hematology. Education Program 2003. link

    Original source

    1. [1]
      Hematology grants workshop.Poncz M, Iannone R, Werner EM Hematology. American Society of Hematology. Education Program (2003)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG